WallStreetZenWallStreetZen

NASDAQ: NUVL
Nuvalent Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NUVL

Based on 7 analysts offering 12 month price targets for Nuvalent Inc

Min Forecast
$100.00+6.08%
Avg Forecast
$116.29+23.35%
Max Forecast
$135.00+43.21%

Should I buy or sell NUVL stock?

Based on 7 analysts offering ratings for Nuvalent Inc.

Strong Buy
Strong Buy
4 analysts 57.14%
Buy
2 analysts 28.57%
Hold
1 analysts 14.29%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NUVL's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates NUVL as a "Sell". Stocks with a Zen Rating of Sell have trailed the market by -4.50%. Learn More

Be the first to know when Wall Street analysts revise their NUVL stock forecasts and price targets.

NUVL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-11-13
lockedlocked$00.00+00.00%2024-10-24
lockedlocked$00.00+00.00%2024-10-04Find Out Why
lockedlocked$00.00+00.00%2024-09-16
lockedlocked$00.00+00.00%2024-09-16
Stifel Nicolaus
Bottom 9%
9
Strong BuyMaintains$135.00+43.21%2024-09-16Find out why
Barclays
Top 17%
84
Strong BuyInitiates Coverage On$100.00+6.08%2024-08-29

1 of 1

Forecast return on equity

Is NUVL forecast to generate an efficient return?

Company
-23.42%
Industry
137.48%
Market
70.82%
NUVL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NUVL forecast to generate an efficient return on assets?

Company
-22.09%
Industry
22.54%
NUVL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NUVL earnings per share forecast

What is NUVL's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$3.84
Avg 2 year Forecast
-$4.56
Avg 3 year Forecast
-$4.91

NUVL revenue forecast

What is NUVL's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$4.8M
Avg 2 year Forecast
$26.8M
Avg 3 year Forecast
$170.7M

NUVL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NUVL$94.27$116.29+23.35%Strong Buy
MDGL$318.55$361.86+13.60%Buy
CORT$59.21$75.25+27.09%Strong Buy
BPMC$97.62$124.55+27.58%Buy
HALO$48.59$61.11+25.77%Buy
View Top Biotech Stocks

Nuvalent Stock Forecast FAQ

Is Nuvalent Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: NUVL) stock is to Strong Buy NUVL stock.

Out of 7 analysts, 4 (57.14%) are recommending NUVL as a Strong Buy, 2 (28.57%) are recommending NUVL as a Buy, 1 (14.29%) are recommending NUVL as a Hold, 0 (0%) are recommending NUVL as a Sell, and 0 (0%) are recommending NUVL as a Strong Sell.

If you're new to stock investing, here's how to buy Nuvalent stock.

What is NUVL's earnings growth forecast for 2024-2026?

(NASDAQ: NUVL) Nuvalent's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.58%.

Nuvalent's earnings in 2024 is -$224,285,000.On average, 6 Wall Street analysts forecast NUVL's earnings for 2024 to be -$273,076,300, with the lowest NUVL earnings forecast at -$295,578,645, and the highest NUVL earnings forecast at -$247,262,905. On average, 6 Wall Street analysts forecast NUVL's earnings for 2025 to be -$323,999,669, with the lowest NUVL earnings forecast at -$391,499,600, and the highest NUVL earnings forecast at -$280,657,608.

In 2026, NUVL is forecast to generate -$348,868,065 in earnings, with the lowest earnings forecast at -$451,894,275 and the highest earnings forecast at -$228,789,240.

What is NUVL's revenue growth forecast for 2025-2027?

(NASDAQ: NUVL) Nuvalent's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.84%.

Nuvalent's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast NUVL's revenue for 2025 to be $341,052,283, with the lowest NUVL revenue forecast at $341,052,283, and the highest NUVL revenue forecast at $341,052,283. On average, 7 Wall Street analysts forecast NUVL's revenue for 2026 to be $1,902,432,267, with the lowest NUVL revenue forecast at $305,526,004, and the highest NUVL revenue forecast at $4,514,679,599.

In 2027, NUVL is forecast to generate $12,126,398,139 in revenue, with the lowest revenue forecast at $2,806,576,081 and the highest revenue forecast at $22,886,029,254.

What is NUVL's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: NUVL) forecast ROA is -22.09%, which is lower than the forecast US Biotechnology industry average of 22.54%.

What is NUVL's Price Target?

According to 7 Wall Street analysts that have issued a 1 year NUVL price target, the average NUVL price target is $116.29, with the highest NUVL stock price forecast at $135.00 and the lowest NUVL stock price forecast at $100.00.

On average, Wall Street analysts predict that Nuvalent's share price could reach $116.29 by Nov 13, 2025. The average Nuvalent stock price prediction forecasts a potential upside of 23.35% from the current NUVL share price of $94.27.

What is NUVL's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: NUVL) Nuvalent's current Earnings Per Share (EPS) is -$3.47. On average, analysts forecast that NUVL's EPS will be -$3.84 for 2024, with the lowest EPS forecast at -$4.16, and the highest EPS forecast at -$3.48. On average, analysts forecast that NUVL's EPS will be -$4.56 for 2025, with the lowest EPS forecast at -$5.51, and the highest EPS forecast at -$3.95. In 2026, NUVL's EPS is forecast to hit -$4.91 (min: -$6.36, max: -$3.22).

What is NUVL's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: NUVL) forecast ROE is -23.42%, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.